Articles tagged with Cancer
Researchers identify new group of immune cells driving autoimmune attack on insulin-producing cells in pancreas during cancer immunotherapy. JAK inhibitors, already FDA-approved for psoriasis and arthritis, show potential to prevent and even reverse type 1 diabetes in preclinical models.
A novel nanocarrier system utilizing metal-polyphenols enables precise intracellular delivery of therapeutic antibodies into cancer cells. This technology overcomes endosomal entrapment, resulting in suppressed tumor growth and enhanced anti-cancer activity.
A recent study discovered that the mutational landscape of blastic plasmacytoid dendritic cell neoplasm (BPDCN) is similar to other myeloid neoplasms. The researchers identified CCDC50 as a potential biomarker for this disease, which showed promising results in tracking disease activity and monitoring treatment success.
Researchers found that elevated L-aspartic acid levels predict gastric cancer risk, while influencing treatment outcomes of Helicobacter pylori eradication and garlic supplementation. This study suggests using plasma L-aspartic acid profiling to tailor prevention efforts and identify high-risk individuals.
A new bioinformatic tool called Cell Marker Accordion has been developed to help researchers understand single-cell analysis results. The tool reveals the presence of altered cells that may be linked to diseases such as blood cancers or solid tumours, and can identify unique genes involved in these alterations.
Rice University professor Lei Li has received a NSF CAREER Award to develop wearable medical imaging technology capable of visualizing deep tissue function in real time. The project aims to miniaturize hospital-grade imaging systems into compact, energy-efficient wearables.
Researchers develop self-assembling nanoparticles that induce ferroptosis in bladder cancer cells while reprogramming the tumor immune microenvironment, boosting anti-tumor activity. The nanomedicine has dual functions as a multifaceted approach to overcome treatment resistance and is Clinically translatable.
A new study from Karolinska Institutet found that adults who have survived childhood cancer are 58% more likely to develop severe COVID-19 if they contract the virus. Despite having a lower risk of infection, childhood cancer survivors experienced more serious consequences when they did become ill.
Recent advances in precision medicine for breast cancer have shown significant progress for each subtype, including HR+/HER2- and HER2-positive breast cancers. Immunotherapy has improved pathological complete response rates and survival for triple-negative breast cancer.
A study by Arc Institute and Stanford University scientists reveals that the target site of a popular STING inhibitor lacks a pocket found in mouse STING, making it challenging to develop effective human treatments. The research proposes targeting STING by preventing oligomerization, a key checkpoint prior to activation.
A new molecular tool, BLOCK-ID, has been developed to study the alternative lengthening of telomeres (ALT) pathway in cancer cells. The tool allows researchers to monitor protein interactions and identify essential proteins like TRIM24, which play a crucial role in ALT telomere maintenance.
The new microscope allows researchers to map and quantify the mechanical properties of biological tissues without interfering with them, enabling real-time monitoring. This breakthrough technology has far-reaching implications for fields such as inflammation, cancer, developmental biology, and biomedical materials.
MIT researchers have designed cheap, disposable electrochemical sensors that can detect multiple diseases using DNA-coated electrodes. The sensors were stabilized with a polymer coating, allowing them to be stored for up to two months, enabling potential use in low-resource regions and at home.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.
A new study from UF Health reveals an antibody-drug conjugate that kills aggressive B cell malignancies while sparing healthy cells. The combination of cancer-hunting antibodies and tiancimycin, a natural compound found in soil microbes, shows promise as a powerful treatment option for diffuse large B cell lymphoma.
Researchers have discovered a protein called BACE1 that helps lung cancer spread to the brain, where treatment options are currently limited. The study suggests that existing Alzheimer's drugs could be repurposed to prevent or slow the spread of lung cancer to the brain.
A new hydrogel-based platform has been developed to preserve live patient-derived tumor tissues in the lab, enabling more accurate testing of cancer treatments. The approach, which uses customizable bioengineered hydrogels, has been shown to retain key features of the original tumor environment.
Researchers identify tumor-associated macrophages that shield tumors from attack and promote metastasis in advanced prostate cancer. Blocking these cells with anti-SPP1 treatment boosts the immune response, slowing cancer progression.
Researchers have identified a single genetic difference in Fas Ligand, an immune protein, that makes it vulnerable to being disabled by plasmin, a tumor-associated enzyme. This vulnerability seems unique to humans and may contribute to the effectiveness of certain cancer treatments.
Researchers have identified WSTF as a protein that could be targeted to block chronic inflammation, allowing the immune system to continue responding appropriately to short-term threats. The study's findings suggest new potential treatments targeting WSTF may combat chronic inflammatory diseases
Researchers developed an innovative FENCY ligation technique combined with preoperative embolization to remove giant plexiform neurofibromas, reducing risk of complications and improving recovery time. The study results in significant functional improvement and high patient satisfaction rates.
Researchers at the University of Illinois Urbana-Champaign have developed a new non-invasive MRI approach that visualizes brain metabolism and detects metabolic alterations associated with brain diseases. The technique uses magnetic resonance spectroscopic imaging to provide insights into brain function and disease processes.
Dysregulation of phosphatases modulates various signaling pathways, including RAS/MAPK, PI3K, HIPPO, and JAK/STAT. This review highlights the tumour suppressive, tumour promoting, and context-dependent activities of phosphatases, as well as their roles in reshaping the tumour microenvironment through exosomal miRNA secretion.
Researchers create a potential treatment for glioblastoma, called MT-125, that makes malignant cells responsive to radiation and chemotherapy. The compound also blocks the cancer's ability to invade other tissue and has shown promise in animal studies.
A new software tool called VR-Omics has the potential to further our understanding of other childhood diseases. The technology can identify previously undetected cell activities of cardiac rhabdomyoma, a type of benign heart tumour that can cause respiratory distress and irregular heartbeat.
Scientists have discovered that CD4 T cells can target tumour cells with high efficiency, expanding the pool of patients who could benefit from this therapy. A clinical trial is currently preparing to test this approach in adults and children with various types of cancer.
The Hospital Internacional de Colombia has joined the Mayo Clinic Care Network, a group of vetted health organizations with access to Mayo Clinic's knowledge and expertise. The network aims to advance high-quality patient-centered care through innovation and collaboration.
A new urine-based tumor DNA test can help personalize bladder cancer treatment by predicting which patients are at higher risk for recurrence after immunotherapy. The test, UroAmp, analyzes urine samples to identify bladder cancer-related mutations and generate a genomic profile for each patient.
Scientists found that blocking PTGIR could help revitalize T cells in their battle against cancer. Prostacyclin interacts with PTGIR to lead to T cell exhaustion, which can be reversed by inhibiting this interaction.
Researchers identified hundreds of molecular markers in saliva associated with systemic pathological processes beyond the oral cavity. These markers can reflect genetic heritability of diseases such as prostate cancer, coronary disease, and Type 2 diabetes.
Researchers discovered two distinct ways mutation of the FOXA1 gene alters tumor formation and therapy resistance in prostate cancer in mouse models. The findings provide insight into how different classes of FOXA1 mutations operate, shedding light on the complex mechanisms driving prostate cancer progression.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
A landmark study found that the tumour immune microenvironment plays a critical role in the progression of nasopharyngeal carcinoma, paving the way for precision oncology approaches. The study discovered distinct molecular differences between NPC subtypes, which influence disease progression and treatment responsiveness.
Dr. Fong showcases advancements in liver surgery, gene therapy, and remote surgery, aiming to make exceptional cancer surgery accessible to everyone worldwide. He also highlights the potential of AI and wearables to improve patient outcomes and enhance surgical precision.
A study by the University of California, Davis found that disposable e-cigarettes release higher amounts of toxic metals than older e-cigarettes and traditional cigarettes. The devices contain hazardous levels of neurotoxic lead, carcinogenic nickel, and antimony, posing significant health risks to users.
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
Researchers identified 'uncommitted' cells in neuroblastoma tumors that exhibit weaker cancer development, potentially leading to favorable outcomes for patients. These cells may help identify early diagnostic markers and novel therapeutic targets.
Researchers developed an AI tool called AAnet to characterize cancer cell diversity, identifying five distinct cell groups with different gene expression profiles. This could lead to more targeted therapies and improved patient outcomes.
A new precision oncology paper presents a case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. The WIN International Molecular Tumor Board proposed personalized treatment plans based on the tumor's unique genetic mutations, highlighting the growing role of precision oncology in guiding th...
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
Scientists at UNIGE have identified MLF2 and RBM15 as key proteins regulating chromatin remodelling, which can go awry leading to cancers and neurological disorders. These two proteins could become promising therapeutic targets for diseases linked to disrupted chromatin remodelling.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
A new study reveals that cancer-fighting immunotherapy drugs may offer benefits to organ transplant recipients with advanced cancer when carefully managed. The study found that about one in three patients responded positively to treatment within a year, with improved survival outcomes comparable to the general population.
Two Purdue researchers received funding to advance university innovations. Andrew Mesecar aims to develop new treatments for hepatocellular carcinoma using patented enzyme inhibitors. Meanwhile, Pablo Zavattieri is working on a patent-pending system to address saltwater intrusion in the Panama Canal.
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
Researchers at UCLA have discovered a chromatin-based strategy that enables cells to rapidly produce proteins when nutrients are scarce. This 'priming' mechanism, driven by the MYC gene, allows cancer cells to adapt and survive under metabolic stress.
CIK cell therapy improved overall and progression-free survival for patients with colorectal cancer, regardless of disease stage. Serum CEA levels can predict treatment response, paving the way for a simple blood test.
Researchers at University of Cologne have discovered a previously unknown mechanism that explains why many patients with aggressive B-cell lymphoma don't respond to CAR-T cell therapy. Combining this innovative treatment with CSF1R inhibitors improves its effectiveness, according to the study published in Cancer Cell.
Recent CAR-T cell modification strategies have enhanced recognition, immunity stimulation, killing activity, and safety. The new designs counteract tumor immune escape and immunosuppressive microenvironments.
Researchers at the University of Missouri have developed a new imaging probe that can help surgeons accurately identify and remove aggressive brain tumors during operations. The tool, known as FA-ICG, uses near-infrared light to highlight tumor cells from within.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
Researchers review classification, mechanisms of action and clinical application of bispecific antibodies in treating non-small cell lung cancer. Bispecific antibodies demonstrate improved anti-tumor efficacy and a safe profile for NSCLC patients resistant to targeted therapies or immune checkpoint inhibitors.
Cancer patients treated with immune checkpoint inhibitors are at risk of heart damage due to rapid loss of protective immune cells. Researchers found a biomarker, CD69, can predict which patients are most at risk and may help doctors monitor them more closely.
Researchers at UCL found that low-risk thyroid cancer patients can safely forego radioactive iodine treatment after surgery, allowing them to spend more time with family. This could impact hundreds of thousands of people worldwide, particularly younger parents and those living in the UK.
The mitochondrial ribosomal protein family (MRPs) is dysregulated in various cancers, influencing tumor initiation and progression. MRPs regulate metabolic reprogramming of immune cells within the tumor microenvironment, affecting growth, migration, invasion, and chemoresistance.
The study highlights the importance of pro-inflammatory cytokines and CXC chemokines in tumor development and immune system modulation. Age-related changes in the tumor microenvironment, including extracellular matrix stiffening and inflammatory immune mediator accumulation, contribute to tumor growth, metastasis, and immune evasion.
Scientists at Xi'an Jiaotong-Liverpool University developed a new nanoparticle capable of carrying high doses of chemotherapy drugs while staying stable for extended periods. This innovation could make treatments more effective and reduce side effects.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.
The University of Texas Health Science Center at San Antonio is targeting hard-to-treat cancers and boosting HPV vaccination rates with a $3.4 million funding from CPRIT. The institution will expand its core facilities laboratories to increase researchers' ability to identify therapeutic targets and develop new cancer technologies.
Researchers found that combining selinexor with Irinotecan shrunk tumors in preclinical models of colorectal cancer, suggesting a new potential treatment. The study also identified XPO1 mutations linked to rare cancers like endometrial cancer and found that these mutations make cells resistant to chemotherapy.